Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII



Status:Completed
Conditions:Anemia, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:Any - 15
Updated:1/13/2019
Start Date:December 2007
End Date:April 2018

Use our guide to learn which trials are right for you!

An Open-label Study To Evaluate Prophylaxis Treatment, And To Characterize The Efficacy, Safety, And Pharmacokinetics Of B-domain Deleted Recombinant Factor Viii Albumin Free (Moroctocog Alfa [Af-cc]) In Children With Hemophilia A

The purpose of this research study is to determine the effectiveness, safety, and
pharmacokinetics (PK) of moroctocog alfa (AF-CC) in previously treated subjects, who are
younger than 6 years of age, with severe or moderately severe hemophilia A.


Inclusion Criteria:

- Male subjects, aged less than 6 years, with moderately severe to severe hemophilia A.

- A negative FVIII inhibitor titer at screening, and a medical history negative for a
past FVIII inhibitor.

- At least 20 exposure days to any FVIII replacement product.

- Adequate hepatic and renal function

- CD4 count > 400 cells/uL, and if receiving antiviral therapy must be on a stable
regimen

Additional criteria for subjects participating in the PK assessment:

- Male subjects as described immediately above except they must have a FVIII Activity of
less than or equal to 1% confirmed by the central laboratory screening test

- Age < 6 years at time of PK assessment.

- The subject's size is sufficient to permit PK-related phlebotomy.

- The subject is able to comply with the procedures conducted during the PK assessment,
including a mandatory 72-hour washout period preceding the PK assessment.

Exclusion Criteria:

- A history of FVIII inhibitor.

- Presence of a bleeding disorder in addition to hemophilia A.

- Treatment with any investigational drug or device within 30 days before the time of
signing the informed consent form.

- Major or orthopedic surgery planned to occur during the course of the study.

- Regular (e.g., daily, every other day) use of antifibrinolytic agents or medications
known to influence platelet function such as aspirin or certain nonsteroidal
anti-inflammatory drugs (NSAIDs), or regular, concomitant therapy with
immunomodulating drugs (e.g., intravenous immunoglobulin [IVIG], routine systemic
corticosteroids).

- Known hypersensitivity to hamster protein.
We found this trial at
8
sites
6113
mi
from 91732
Buenos Aires,
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
5323 Harry Hines Blvd
Dallas, Texas 75235
(214) 648-3111
Univ of Texas, Southwestern Med Ctr of Dallas The story of UT Southwestern Medical Center...
1221
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
827
mi
from 91732
Portland, OR
Click here to add this to my saved trials
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
University of Utah Research is a major component in the life of the U benefiting...
572
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
1935 Medical District Dr
Dallas, Texas 75235
(214) 456-7000
Children's Medical Center of Dallas Children's Medical Center is private, not-for-profit, and is the fifth-largest...
1221
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Portland, Oregon 97239
826
mi
from 91732
Portland, OR
Click here to add this to my saved trials
Salt Lake City, Utah 84143
572
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials